
OrCam Plans $3 billion Valuation in 2021 IPO
OrCam Technologies Ltd, founded and run by Prof Amnon Shashua and Ziv Aviram, is set to go public in New York during 2021, reported by

Nanox’s Next Generation Radiology Rocks the RSNA 2020!
NANO-X IMAGING LTD (NASDAQ: NNOX) successfully demonstrated its Nanox.ARC next-generation x-ray prototype at the 2020 annual conference of the Radiological Society of North America (RSNA),

Alpha TAU Medical raises $26 million funding as it moves to Jerusalem
Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, finished in June the closing of a Series B equity financing of $26

FDA Accepts Atox Bio’s Reltecimod to Treat Suspected Organ Dysfunction/Failure re “Flesh-Eating Disease”
The U.S. Food and Drug Administration (FDA) has accepted to Atox Bio’s filing of the New Drug Application (NDA) for Reltecimod with a Prescription Drug

Ascento Medical Gives New Hope for Alzheimer’s and Dementia Patients
Ascento Medical is a company in the field of Dementia and Alzheimer’s treatment & prevention, using Artificial Intelligence and Machine Learning to optimize a proven

KAHR Announces First Patient Dosed in DSP107 Treatment of Solid Tumors Phase 1/2 Clinical Trial
Jerusalem based KAHR MEDICAL, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, started treating the first patient in its Phase 1/2 clinical trial (NCT04440735)

Raziel Closes Market License Agreement for RZL 012 with Fosun Pharma
Raziel Therapeutics, a Pharmaceutical company, is developing a novel synthetic small molecule (NCE) for aesthetics and fat disorders next-generation novel prescription products. Raziel Therapeutics licensed

Oramed to Start Pivotal Phase 3 Oral Insulin Studies
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company is about to start their Phase 3 Studies for their oral insulin candidate

Omnix Medical Raises $8.5 million for its Novel Drug Targeting AMR Bacteria
Omnix Medical just raised an additional $8.5 million to bring its promising AMR (antimicrobial resistance) drug, OMN6, for the treatment of hospital-acquired infections, to clinical